Here, we summarize the current state of the science on NAMPT inhibitor resistance in cancer, focusing on altered regulation of compensatory NAD+ synthesis pathways, drug target mutations, metabolic adaptations, and drug transporters [Figure 2]. The gene discussed is NAMPT; the disease is cancer.